Tue, Sep 16, 2014, 2:55 PM EDT - U.S. Markets close in 1 hr 5 mins

Recent

% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

  • superforce_57 superforce_57 Jun 10, 2013 6:39 PM Flag

    Anyone think AMPE has an idea of how the trials are going?

    ..in their rebuttal to the Seeking Alpha bash article, thay didn't say they were confident in their drugs, they said they were "very confident". AMPION run in trial is finished, now they are analyzing the data. The bar is low for efficacy for Ampion, because synvisc's efficacy is so marginal.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The trials for both Ampion and Optina are so far in that of course the company knows exactly how well they are doing but they are legally restrained from saying anything.

      They are just sitting back and smiling because they know what we don't.

      Actually, based on Ampion's previous trial and an interview with the CRO who directed the 100 patient trial, Ampion should sail to a successful conclusion. I wouldn't be surprised if the doctors involved in the trials aren't trying to figure our when they can legally buy stock.

      And based on prior results and based on the actual mechanism, Optina should also sail to a mind blowing successful conclusion.

      And Zertane . . . we already heard in the recent UBS interview from Macaluso . . . they expect to announce the partner "VERY SOON".

      Hang in there because this will be a very exciting next few months for AMPE.

      I predict very big numbers for the shares before year end and unbelievable numbers in the next two and three years that will astound even the most bullish Ampio fan.

      Sentiment: Strong Buy

    • My guess is that they are very confident. Very!

      Sentiment: Strong Buy

 
AMPE
3.6489-0.0011(-0.03%)2:53 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.